BMC Cancer

Table 5 Overall and Disease-Free Survival using Kaplan-Meier and log-rank test but only in patients who received complete chemotherapy regimen (all of whom received gemcitabine)

From: Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

		Overall Survival				Disease-Free Survival
Covariate		Median [months] (95% CI)	N	Total N	Log-rank p-value	Median [months] (95% CI)	N	Total N	Log-rank p-value
Overall		20.3 (15, 25.5)	82	82		13.5 (9.3, 19.4)	62	62
Age	Young (≤ 65.5)	22 (15.6, 47.2)	44	82	0.18	10.5 (8, 19.3)	38	62	0.48
	Old (> 65.5)	17 (9.6, 25.5)	38			14 (8, ∞)	24
Size	Small (≤ 2.0)	25 (9.6, 47.2)	18	82	0.45	20.5 (8.3, ∞)	12	62	0.21
	Large (> 2.0)	17.7 (14.8, 25.5)	64			12 (8, 17.3)	50
Gender	Female	22 (14.8, 34.5)	36	82	0.85	10 (6.5, 17.3)	31	62	0.12
	Male	20 (14.4, 25.5)	46			19.3 (9.4, 46)	31
Race	White	20 (14.8, 26.5)	59	82	0.88	13.5 (8, 25.5)	42	62	0.65
	Non-White	22 (9.2, 26.2)	23			10.3 (5.5, 592)	20
Grade	1/2	20.5 (16, 25.5)	67	82	0.028	14 (10.3, 20.5)	51	62	0.0503
	3/4	14.5 (6.5, 26.5)	15			9.4 (2, 25.5)	11
Lymph Nodes	0	25.5 (15, 48.5)	26	81	0.038	20.5 (13.5, ∞)	20	61	0.012
	≥ 1	16 (13, 20.3)	55			9.4 (6.5, 14)	41
Tumor	1/2	20 (6.5, 47)	13	82	0.59	19.5 (5.5, ∞)	8	62	0.21
(TNM)	3/4	20.5 (15, 26)	69			12 (8, 19.3)	54
RRM1	Low	20.3 (15, 25.5)	55	81	0.87	13.5 (8, 20.5)	39	61	0.84
IHC Interp	High	47.8 (8.7, 48)	26			16.6 (5.5, ∞)	22
RRM1	Low	24 (17, 26)	37	44	0.070	14 (9.4, 25.5)	26	32	0.62
PCR Interp	High	48 (, )	7			17.3 (10.5, 17.3)	6
ERCC	Low	20.3 (14.8, 26.5)	35	82	0.88	14 (9.4, 31.5)	25	62	0.36
IHC Interp	High	17 (13.3, 26)	47			12 (6.5, 20.5)	37
ERCC	Low	17 (14.5, 24.7)	39	68	0.23	10 (7, 25.5)	28	54	0.74
PCR Interp	High	24 (11, 63.7)	29			13.5 (8, 20.5)	26

* The 95% confidence interval could not be estimated since only one event (death) was recorded.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com